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Glioblastoma  multiforme  (GBM)  is a grade  IV astrocytoma  and  the  most  common  malignant
brain tumor.  Current  therapies  provide  a median  survival  of 12–15  months  after  diagnosis,
due  to the  high  recurrence  rate.  The  failure  of  current  therapies  may  be due  to the  presence,
within the  tumor,  of  cells  characterized  by enhanced  self-renewal  capacity,  multilineage
differentiation  potential  and  elevated  invasive  behavior,  called  glioma  stem  cells  (GSCs).
To evaluate  the  pharmacological  efﬁcacy  of selected  drugs  on six GSC  lines,  we set  up  a
multiple  drug  responsivity  assay  based  on  the combined  evaluation  of  cytomorphological
and  functional  parameters,  including  the  analysis  of  polymorphic  nuclei,  mitotic  index  and
cell viability.  In order  to  understand  the  real  pharmacological  efﬁcacy  of the  tested  drugs,
we assigned  a speciﬁc  drug  responsivity  score  to  each  GSC  line,  integrating  the  data  pro-
duced  by  multiple  assays.  In this  work  we  explored  the  antineoplastic  effects  of  paclitaxel
(PTX), an  inhibitor  of microtubule  depolymerization,  utilized  as  standard  treatment  in sev-
eral cancers,  and of  valproic  acid  (VPA),  an  inhibitor  of  histone  deacetylases  (HDACs)  with
multiple  anticancer  properties.  We  classiﬁed  the six  GSC  lines  as  responsive  or resistant
to  these  drugs,  on the  basis  of their  responsivity  scores.  This  method  can  also  be  useful
to  identify  the  best  way  to combine  two or more  drugs.  In  particular,  we  utilized  the  pro-
differentiating  effect  of VPA  to  improve  the  PTX  effectiveness  and we  observed  a  signiﬁcant
reduction  of cell  viability  compared  to single  treatments.
© 2014  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is  an  open  access  article  under
Y-NC-Nthe CC  B
1. IntroductionGlioblastoma multiforme (GBM) is the most frequent
and aggressive primary tumor of the central nervous sys-
tem,  deﬁned as grade IV astrocytoma (WHO classiﬁcation)
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[40]. Despite aggressive multimodal therapies, such as
surgical  resection, chemo- and radiotherapy, the median
survival of patients remains about 12 months, because
of  rapid tumor recurrence [62]. The differences in drug
sensitivity, even in the same histological type of tumor,
could be explained by the extremely heterogeneous land-
scape  of genetic alterations and gene expression patterns
of  GBM [65,25,26]. On the other hand, an explanation
for resistance both to radiation and chemotherapy and
eventual tumor relapse was imputed to speciﬁc tumor
cells endowed with stem-like properties, the glioma stem
is is an open access article under the CC BY-NC-ND license
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ell (GSC) subpopulation [47,38,39]. Evidences prove that
SC  lines represent a valuable biological in vitro model of
BM,  as they are more representative of the respective pri-
ary  tumor [35]. GSCs are characterized by an enhanced
elf-renewal capacity and a severe impairment of the
ifferentiation potential, due to a permanent epigenetic
lock [2,58]. These ﬁndings suggest the crucial importance
f  the development of GSC-targeted therapy in order
o  speciﬁcally eradicate the stem cell compartment of
he  tumor. Overcoming the differentiation block could
onstitute an interesting therapeutic strategy [53].
Recently, the lack of consistency in cell viability data
btained in different laboratories on the same cell lines
reated with the same compounds has underlined the
mportance of simultaneously evaluating multiple cell
arameters to carefully determine the pharmacological
ffectiveness of the tested drugs [3,19,21,61].
Aim of this study was  to develop a novel drug respon-
ivity multiple assay based on the combined evaluation
f cytomorphological and functional parameters to assess
he  pharmacological effectiveness of the tested drugs. In
articular,  we investigated both morphological and cyto-
enetic  parameters, directly or indirectly involved in the
ytotoxic  action of the tested molecules, such as polymor-
hic nuclei and mitotic index, in addition to cell viability.
he  different biological nature of these data required the
ormulation of a method to evaluate them simultaneously
n order to understand the real pharmacological efﬁcacy
f  the tested compounds. In this work, we used, as exam-
le  of antineoplastic drugs, paclitaxel (PTX), an antimitotic
rug [13], and valproic acid (VPA), an anticonvulsant and
ood-stabilizing drug [15], on six GSC lines. These com-
ounds are both used in treatment and management of
everal  cancers and are different in their molecular activi-
ies:  VPA is a histone deacetylases (HDAC) inhibitor, while
TX  is an inhibitor of microtubule depolimerization. Our
ultiple  drug responsivity assay has proven itself useful
n  identifying how to best carry out a combined treatment
f  these two drugs. In fact we evaluated the therapeutic
dvantage of a sequential treatment with VPA followed
y  PTX in comparison with the treatment with a single
rug. We  advanced a therapeutic strategy based on the
hemosensitization of GSCs, determined by the induction
f  cellular differentiation, and the consequent treatment
ith a standard antiproliferative drug.
. Materials and methods
.1.  Cell lines and cell culture conditions
The six GSC lines used in this work (GBM2, GBM7, G144,
166, G179 and GliNS2) have been isolated from patients
ffected by GBM [20,45] and in 2013, our research group
haracterized their cytogenomic and epigenomic proﬁles
2].  The stemness properties of the GSC lines were peri-
dically monitored, as already described [2]. Cells were
ultured in adherent culture condition using 10 g/ml
aminin (Invitrogen) in a proliferation permissive medium
omposed by DMEM F-12 and Neurobasal 1:1 (Invitro-
en), B-27 supplement without vitamin A (Invitrogen),
 mM L-glutamine, 10 ng/ml recombinant human bFGFrts 1 (2014) 188–199 189
and  20 ng/ml recombinant human EGF (Miltenyi Biotec),
20UI/ml penicillin and 20 g/ml streptomycin (Euroclone)
(complete medium).
2.2.  Drugs and treatments
Valproic  acid (sodium salt, Sigma) was  dissolved in ster-
ile  water to a stock concentration of 50 mg/ml  and stored at
−20 ◦C. Paclitaxel (Lc laboratories) was dissolved in abso-
lute  ethanol to 10 mM stock concentration and then diluted
to  the required concentrations, with complete cell culture
medium. The ﬁnal concentration of ethanol was no greater
than  0.1%. This concentration of solvent had no effect on
cell  viability (measured by MTT  assay). Dose–response
studies were carried out in order to determine the suit-
able  doses for further experiments. Cell culture treatments
were assessed following two  different schedules of admin-
istration: (i) single drug treatment was performed using
0.5–1–3–6–10–20 mM VPA or 0.01–0.1–1–10–20–50 M
PTX for 24, 48 and 72hs and (ii) dual drug treatment was
performed treating cells with different concentrations of
VPA  for 24 h and then adding PTX at different concentra-
tions for 48 h (Fig. S1).
Supplementary Fig. 1 can be found, in the online version,
at  doi:10.1016/j.toxrep.2014.05.005.
2.3. Cytomorphological analysis
Cells were seeded in T-25 cm3 at a concentration of
0.4  × 106 cell/ml. When cells reached the 80% conﬂuence,
they were treated with 2 mM VPA or with 10 M PTX for 24
and  48hs. Subsequently, chromosomal preparations were
performed by means of standard procedures as previously
described [2]. Brieﬂy, chromosomes were QFQ-banded
using quinacrine mustard and slides were mounted in McIl-
vaine  buffer. Slides were analyzed using Nikon Eclipse
80i  ﬂuorescence microscope (Nikon) (60× magniﬁcation)
equipped with a COHU High Performance CCD cam-
era. Cytomorphological parameters were analyzed using
preparations derived from the same cell passage. Mitotic
index and polymorphic nuclei were evaluated counting the
percentage  of mitosis and aberrant nuclei, scoring at least
1000  nuclei. Data were obtained as mean values, derived
from  two independent experiments using cells at different
passages.
For  the cellular morphological study, cells were seeded
in  6-well plates without laminin coating in proliferative
permissive medium at 3 × 103–104 cells/ml, depending
on the growth rate of each cell line, and after 24 h,
cells were treated with VPA (0.5–1–6–10 mM)  or PTX
(0.1–1–10–20–50 M)  concentrations for different times
of  exposure (24, 48 and 72 h). The presence of morpho-
logical changes was estimated through the observation at
phase  contrast microscopy, comparing VPA or PTX-treated
and untreated cells. Representative images were taken for
each  cell line and for each treatment.2.4. Whole chromosome painting FISH
FISH was  performed on interphasic nuclei using Whole
Chromosome Painting (WCP) probes. Particularly, we
gy Repo190 G. Riva et al. / Toxicolo
utilized the Octochrome Chromoprobe Multiprobe System
(Cytocell, Cambridge, UK) and procedures were performed
according to the manufacturer’s protocol. A minimum of
100  nuclei was evaluated for each speciﬁc square.
2.5. Immunoﬂuorescence
The immunoﬂuorescence assays were performed on
untreated and 2 mM VPA-treated cultures for 72 h. The
experiments were performed on all GSC lines using rab-
bit  anti-CD133 (Santa Cruz Biotechnology, Santa Cruz, CA,
USA;  1:50), mouse anti-nestin (Millipore, Billerica, MA,
USA;  1:50), rabbit anti-glial ﬁbrillary acidic protein (GFAP,
Dako,  1:200), rabbit anti-III tubulin (Covance, 1:100) and
goat  anti-Myelin basic protein (MBP, Santa Cruz Biotech-
nology, 1:50) as primary antibodies. Cells were placed
onto slides by means of Cytospin, washed with Dulbecco’s
modiﬁed phosphate-buffered saline (PBS), ﬁxed with 4%
paraformaldehyde for 15 min  and treated for 10 min  with
0.1  M glycine (in PBS). Slides were incubated 30 min  at
room  temperature (RT) in blocking solution (5% Bovine
serum albumin, BSA, 0.6% Triton X-100 in PBS) and treated
for  30 minutes with 70 U/mg RNAse (Sigma–Aldrich, Milan,
Italy;  1:30) in blocking solution. Cells were incubated
with the primary antibodies at 4 ◦C overnight. Then, slides
were  rinsed with washing buffer (0.3% Triton X-100 in
PBS)  and incubated with secondary ﬂuorescent antibod-
ies  and 2.5 mg/ml  propidium iodide (PI) for 1 h at RT.
Alexa Fluor 488-conjugated goat anti-mouse or anti-rabbit
and  donkey anti-goat (Molecular Probes Eugene, OR, USA;
1:200)  were used as secondary antibodies. Alexa Fluor 647-
conjugated  phalloidin (Molecular Probes, Eugene, OR, USA;
1:200)  was used to visualize the actin ﬁlaments. Then, cells
were  washed with PBS and coverslips were mounted using
Polyvinyl alcohol mounting medium (Fluka Analytical,
Milan, Italy). Fluorescent cell preparations were examined
using a Radiance 2100 confocal microscope (Bio-Rad, Her-
cules,  CA, USA). Noise reduction was achieved by Kalman
ﬁltering during acquisition. In order to perform a semi-
quantitative analysis, the number of immunoreactive cells
was  counted, evaluating at least 100 cells per sample over
different areas of the slide. Staining intensity was  classi-
ﬁed  in 5 categories: negative (−; 0–20% of immunoreactive
cells); marginal (±; 21–40%); low (+; 41–60%); medium (++;
61–80%);  and high (+++; 81–100%)[37]. Any statistical sig-
niﬁcant  difference between treated and untreated cells was
evaluated  by Fishers exact test on raw data.
2.6. Cell viability
MTT  assays were performed to evaluate the efﬁcacy
of antineoplastic drugs. Cells were seeded at a den-
sity of 2–4 × 104 cells/well in a 96-well-plate in 100 L
of  culture medium and incubated at 37 ◦C. We treated
cells at passages similar to the ones used for cyto-
morphological analysis. After 24 h, drugs were added to
complete cell culture medium at various concentrations.
After the drug incubation time (24, 48, 72 h), MTT  solu-
tion  (0.5 mg/ml, Sigma) was added to each well and
incubated for 3 h at 37 ◦C. Therefore, formazan was sol-
ubilized in absolute ethanol. The absorbance of the dyerts 1 (2014) 188–199
was  measured spectrophotometrically at a 595 nm wave-
length  using an automated microplate reader (Bio-Rad).
The percentage of inhibition was determined by compar-
ing  the absorbance values of drug-treated cells with that
of  untreated controls: [(treated-cell absorbance/untreated
cell absorbance) × 100]. The results reported are the mean
values of two different experiments performed at least in
triplicate.
2.7.  Cooperative index
To  evaluate the effects of combined VPA-PTX
treatment, the Cooperative Index (CI) was  calculated
comparing the sum of cell death percentages obtained
for each single agent to the percentage of cell death
upon combined treatment (CI = VPA cell death% +
PTX cell death%/Combined treament cell death%). CI
values < 1 indicate a synergistic effect, CI values = 1 an
additive effect, while CI values > 1 indicate an antagonistic
effect [1].
2.8.  Statistical analysis
Statistical  analysis was performed using chi-square,
Fisher’s exact test or t-test on raw data, by means of
Excel spreadsheet (Microsoft Ofﬁce 2007, Microsoft Cor-
poration) or OpenEpi software v2.3.1, available online at
http://www.openepi.com/.  The critical level of signiﬁcance
was set at p < 0.05.
3. Results
3.1. Cell viability after single treatments with VPA or PTX
The  effect of VPA and PTX on the cell viability of the
GSC lines was  determined by MTT  assay (Fig. S1A). The
inhibitory effect on viability of both drugs was  heteroge-
neous among the six cell lines. VPA treatment inhibited cell
viability  in a dose- and time-dependent manner in all the
GSC  lines. As shown in Fig. 1, GBM2 was the most sensitive
cell  line to VPA treatment, showing a decrease in cell viabil-
ity  at all doses after 48 h and 72 h treatments, while after
24  h cells were only sensitive at the highest doses of the
drug.  The other ﬁve GSC lines showed a consistent reduc-
tion  in cell viability only at 72 h of 20 mM VPA treatment.
PTX was  less effective than VPA, in fact ﬁve out of six cell
lines  were relatively resistant to PTX treatment and a con-
siderable inhibition of metabolic activity (GBM7 40%, G144
20%,  G166 26%, G179 32% and GliNS2 30%) was  observed
only at the highest concentration (50 M)  and after the
longest time of treatment (72 h). GBM2 cell line, instead,
exhibited the greatest inhibitory effect on cell viability after
PTX  treatment, mainly at 48–72 h of exposure: for exam-
ple,  PTX 50 M for 72 h induced a signiﬁcant decrease in
cell  viability of approximately 70% (Fig. 1, Table S1).
Supplementary Table 1 can be found, in the online ver-
sion,  at doi:10.1016/j.toxrep.2014.05.005.Since  for therapeutic purposes it is important to use
the  lowest possible pharmacological concentration to
minimize side effects, for all subsequent experiments we
decided  to use an intermediate VPA dose (2 mM).  This
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SEM)  was  constantly lower than 5% of each mean value.
oncentration was set as a consequence of the observation,
fter 24 h treatment, of a shift in cell viability and a
iversiﬁcation of drug susceptibility among the cell lines
aising  the dose from 1 mM (no effect) to 3 mM (effect).
egarding to PTX concentration, we selected a 10 M dose,
ecause,  after 24 h of treatment, it allowed the maximum
eduction of viability in all the cell lines (Fig. 1).
.2. Polymorphic nuclei
The  presence of aberrant nuclei, which are a hallmark of
ancer,  was evidenced in all the GSC lines analyzed, either
reated  or untreated. The nuclear shapes were irregular,
arious and resembled the aberrant nuclear structures
f GBM histological preparations (Fig. S2A), thus rep-
esenting a typical cancer-related feature. We  observed
onut-shaped, ring-shaped, polylobate and fragmented
uclei, nuclei with multiple blebs and the remarkable pres-
nce  of micronuclei (Fig. S2B).
Supplementary Fig. 2 can be found, in the online version,
t  doi:10.1016/j.toxrep.2014.05.005.
After PTX treatment, the presence of defective mitotic
gures, such as uncondensed chromatin threads, chro-
osome fragmentation and de-condensed chromosomes,ell viability was  measured as percentage of cell survival in drug-treated
 experiments performed at least in triplicate. Standard error of the mean
arranged in nuclei-like structures was  noticed (Fig. S2C).
Chi-square test was  assessed to identify any statistically
signiﬁcant difference between treated and untreated cells
(Table  S2). The statistical analysis allowed us to catego-
rize GSC lines in two main groups. The ﬁrst group included
GBM7, G144, G166 and G179 cell lines: they showed a
very  high percentage of polymorphic nuclei in untreated
cells (80–90%) and, therefore, a shift in the percentage of
aberrant nuclei after drug exposure could not be appre-
ciated. The second group was  represented by GBM2 and
GliNS2  cell lines, which had a low percentage of polymor-
phic nuclei in untreated cells (approximately 15% and 10%,
respectively). In this group, both VPA and PTX induced a
signiﬁcant  increase in polymorphic nuclei at 24 (except for
GliNS2  line treated with VPA) and 48 h of treatment, com-
pared  to the corresponding untreated cells (Fig. 2, Table
S2).  After PTX administration, the increment of polymor-
phic nuclei was time-dependent and higher than after VPA
administration (Fig. 2, Table S2).
Supplementary Table 2 can be found, in the online ver-
sion,  at doi:10.1016/j.toxrep.2014.05.005.
To  conﬁrm that the ﬁgures observed referred to aberrant
nuclei and were not the consequence of entosis-like mech-
anisms  [31], we performed chromosome preparations
192 G. Riva et al. / Toxicology Reports 1 (2014) 188–199
treated
of metaphases, but this trend reversed after 48 h, when MI
resulted  signiﬁcantly decreased if compared to untreated
cells.Fig. 2. Percentages of polymorphic nuclei in VPA or PTX treated and un
***p  < 0.0001.
without the use of hypotonic solution, in order to pre-
serve  the original nuclear architecture. We  found that
the  nuclear aberrant shapes were almost maintained by
the  corresponding metaphases (Fig. S3 – top), demostrat-
ing that the several nuclear structures within a cell,
including nuclear fragments and micronuclei, synchron-
ically undergo mitosis, thus excluding the presence of
entosis-like mechanisms.
Supplementary Fig. 3 can be found, in the online version,
at  doi:10.1016/j.toxrep.2014.05.005.
In order to rule out the possible preferential localization
of each chromosome in micronuclei and/or nuclear frag-
ments,  FISH analysis was performed on interphasic nuclei
of  untreated cells using WCP  probes. As shown in Fig. S3
–  bottom, we observed a random chromosome localiza-
tion within these aberrant structures, suggesting the lack
of  speciﬁc patterns.
3.3.  Mitotic index
The  mitotic activity is a crucial parameter to measure
the aggressiveness of a tumor and it is therefore asso-
ciated with important clinical implications. To study the
effects  of VPA and PTX exposure on cellular proliferation,
we evaluated the mitotic index (MI) in chromosome prepa-
rations.  VPA administration determined a decrease of MI
in  all the cell lines analyzed both at 24 and 48 h of treat-
ment, while PTX determined a time-dependent decrease
of  MI  only in GliNS2 and G179 cell lines (Fig. 3). PTX had
no  effect on G144 and GBM7 cell lines, while, in the G166
cell  line, it signiﬁcantly reduced the MI  only after 48 h of cells. Chi-square test, treated vs. untreated cells: *p < 0.05; **p < 0.001;
exposure.  GBM2 cell line showed a peculiar behavior: the
24  h administration induced a considerable accumulationFig. 3. VPA and PTX effects on mitotic index of GSC lines. Results are
reported as percentages, resulting from means of two independent exper-
iments. Chi-square test on raw data: *p < 0.05; **p < 0.0001.
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Table 1
Drug  responsivity index. In the table below, we  reported the scores (from −3 to +3) assigned to p-values of all the experiments, evaluating also the
therapeutic  goodness of the speciﬁc data expressed by algebraic signs (+ or −), performed in order to obtain a ﬁnal index of drug sensibility for each cell
line.
Cell lines Mitotic index Polymorphic nuclei MTT  Drug responsivity index
VPA PTX VPA PTX VPAa PTXb VPA 24/48 h PTX 24/48 h
24 h 48 h 24 h 48 h 24 h 48 h 24 h 48 h 24 h 48 h 24 h 48 h
GBM2 +1 +3 −3 +1 −1 −2 −3 −3 +1 +3 0 +3 5 −5
GBM7 +1 +3 0 0 0 0 0 0 0 0 0 +1 4 1
G144 +3 +3 0 0 0 0 0 0 0 0 0 +1 6 1
G166 +3 +3 0 +1 0 0 0 0 +2 +1 0 0 9 1
G179 +3 +3 +3 +3 0 0 0 0 0 0 0 +1 6 7
GliNS2 +3 +3 +3 +3 0 −3 −3 −3 0 0 0 0 3 0
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a Vpa 3 mM.
b PTX 10 M.
.4. Multiple drug responsivity assay
In order to assess the pharmacological efﬁcacy of the
ested compounds, we developed a rapid, inexpensive
nd simple method that allowed us to combine the data
btained through the analysis of different parameters. We
ssigned  a score (from 1 to 3) to each parameter, depending
n  p-values: speciﬁcally, we attributed the score of 1, 2 or 3
o  p-value < 0.05, 0.001 or 0.0001, respectively. Moreover,
n  order to suggest an interpretation of the therapeutic
oodness of the results we assigned a positive or negative
ign  to each score. In particular, a statistically signiﬁcant
eduction of cell viability, MI  and polymorphic nuclei per-
entages  were considered as good events for therapeutic
urposes and we assigned them positive values of the score.
onversely, increases in these parameters were interpreted
s  unfavorable events for therapeutic purposes and their
cores  were negative. The scores obtained from the 24 and
8  h treatments were added together in order to indicate
he  cell line’s general susceptibility to the drug and the alge-
raic  sum of the scores obtained from the three parameters
epresents its drug responsivity index.
G144, G166 and G179 lines had the highest VPA respon-
ivity indexes (6, 9 and 6, respectively) suggesting a
igniﬁcant sensitivity to this drug; the other lines displayed
 more modest response to VPA.
With regard to PTX, G179 line reached a high score (7),
emonstrating a strong susceptibility to the drug. GBM2
nd  GliNS2 lines showed scores which suggested their
esistance to PTX (-5 and 0, respectively), while the others
ere  weakly responsive (Table 1).
.5. Cellular morphology
VPA  and PTX effects on the six GSC lines were also evalu-
ted  at morphological level. GSCs were seeded as described
n  Section 2 and, after 24 h, they were treated with sev-
ral  concentrations of VPA or PTX. Matching untreated cells
ere  used as control. Subsequently, both cultures were
bserved with a phase contrast microscope at different
ime points (24–48–72 h). GSCs of untreated controls grew
n  non-adherent growth pattern as neurosphere.
VPA treatment determined drastic morphological
hanges in all the GSC lines, compared to controls.ﬁcant; score ≥ 1, responsive; score ≤ 0, resistant.
Cells modiﬁed their morphology from round spheres to
adherent  cells. Most cells were star-shaped with cellular
astrocytic-like processes indicating a pro-differentiating
effect of VPA. In particular, GBM2, G179 and GliNS2 lines
showed differentiated-like morphology changes after 24 h
treatment  with the lowest pharmacological concentration
(0.5 mM).  Regarding the G144 line, the ﬁrst morphological
variations were appreciable after 48 h of exposure to 1 mM
VPA.  Finally, GBM7 and G166 lines began to differentiate
when exposed to 6 mM VPA. It should be noted that the
highest concentrations of VPA (6 mM and 10 mM)  caused,
at  the longest time of exposure, the appearance of dead
cells  and large quantities of cellular debris in GBM2 and
G179  cell lines (Fig. S4).
Supplementary  Fig. 4 can be found, in the online version,
at  doi:10.1016/j.toxrep.2014.05.005.
As expected, PTX-treated GSCs did not show any rele-
vant morphological variations (data not shown).
3.6. Analysis of stemness and differentiation markers by
immunoﬂuorescence
The  pro-differentiating ability of VPA was evaluated
through the expression analysis of selected stemness
(CD133 and Nestin) and differentiation markers (GFAP,
ˇ  III tubulin and MBP), that have been previously used
in  literature [24,57,36,45], comparing untreated cells
versus 2 mM-72 h VPA treated cells. The overview of data
showed that GSCs expressed both stemness and differen-
tiation markers at variable levels. Generally, Nestin was
expressed at medium or high intensity in all untreated
cell lines (range: 63.1–99.2%). CD133 immunoreactive cells
were  found as a large proportion of untreated GSCs in
5/6  cell lines (62.7–100%). Only G166 cell line showed
almost a negative expression of this marker (only 7.3%
of  CD133+ cell). Untreated cells of all GSC lines were
also variously positive for differentiation markers. Thus,
an  aberrant co-expression of differentiation markers with
stem/progenitor markers was not rare: in fact, the tumor
sphere population is heterogeneous and GSC cultures reca-
pitulate  in vitro the hierarchical organization of tumor
itself, being composed by stem-like, transient amplifying
progenitors and differentiated cancer cells [57]. VPA treat-
ment  caused a change in the percentage of cells positive
194 G. Riva et al. / Toxicology Reports 1 (2014) 188–199
ed (u/t) 
propidiuFig. 4. Selected representative images of immunoﬂuorescence on untreat
using  cytospin). Each speciﬁc maker is in green; phalloidin is in blue and 
for at least one stemness marker in 4/6 lines. GBM2 and
G166  cell lines showed a decrease in Nestin immunore-
active cells from 75.4% to 53.8% and from 78.3% to 53.7%,
respectively. Both cell lines displayed also a decrease in
CD133  positive cells, but this variation was not statisti-
cally signiﬁcant. VPA treatment on GliNS2 line induced a
reduction  of CD133 expression of approximately a half,
from  100% to 55.5%. In G179 cell line, Nestin expression was
relatively  preserved after drug treatment, whereas a little
decrease (but not statistically signiﬁcant) in CD133 expres-
sion  was observed. Surprisingly, GBM7 cell line showed
an  increased expression of Nestin after VPA treatment.GSCs and 2 mM VPA treated GSCs (+VPA) for 72hs (spotted on glass slides
m iodide in red. Scale bar = 100 m.
After VPA administration, three cell lines (GBM2, GBM7 and
G166)  exhibited a progressive enrichment in cells express-
ing  ˇIII tubulin, indicating the capability of these cells to
move  toward neuronal differentiation. In addition, GBM7
cell  line showed an increased expression of GFAP positive
cells.  On the contrary, G144 cell line manifested a reduc-
tion  of ˇIII tubulin-positive cells. The other cell lines did
not  show any variation in differentiation marker expres-
sion,  maybe due to the high expression rate observed also in
untreated  cells. Unfortunately, MBP  immunostaining was
not  informative, as its expression remained constant after
treatment (Table S3, Fig. 4).
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Supplementary Table 3 can be found, in the online ver-
ion,  at doi:10.1016/j.toxrep.2014.05.005.
.7.  Effect of VPA-PTX combined treatment on cell
iability
The most effective therapeutic approach to cancer
equires, for the majority of patients, the administration
f a combination of drugs, in the context of speciﬁc multi-
odal  chemotherapies with different molecular targets.
In  this study, we tested the effect of VPA plus PTX
ombined treatment on GSC viability by MTT  assay. The
roposed therapeutic strategy contemplates an epigenetic
witch triggered by VPA, which could modify the stem-like
eatures of GSCs, inducing a differentiation-like process,
ollowed by a PTX exposure. In particular, GSCs were
reated with VPA 24 h before PTX administration; then,
PA  and PTX were incubated together for further 48 h
nd  subsequently cell viability was assessed via MTT assay
Fig.  S1B). The rationale for the time-scheduled administra-
ion of VPA prior to PTX was related to the differentiation
nduction triggered by the former (as evidenced by the
orphologic analysis) and the inhibition of cell prolifer-
tion, through cell cycle arrest and induction of apoptosis,
aused by the latter. Pretreatment of the cells with dif-
erent concentrations of VPA signiﬁcantly increased PTX
ffects  (Fig. 5). However, since the sensitivity to the com-
ined  treatment varied among the GSC lines, its effect was
valuated through the cooperative index (CI) [1] (Table S4).
Supplementary Table 4 can be found, in the online ver-
ion,  at doi:10.1016/j.toxrep.2014.05.005.
G166  cell line was the least sensitive to the combined
reatment, which resulted antagonistic in the majority of
ose  combinations; in particular, a synergistic effect was
oticed  only combining the highest concentrations of PTX
10–20-50  M) and VPA (6–10 mM).  GBM2, GBM7, G144,
179  and GliNS2 cell lines showed a different pattern of
iability  inhibition after the coupled administration. Gen-
rally,  a marked synergistic effect of VPA and PTX was
oticed at the lowest doses of VPA (0.5 and 1 mM),  regard-
ess  of PTX concentration. Speciﬁcally, GBM7 and G144
ell  lines also displayed a signiﬁcant increase in cell death
ombining the highest doses of both drugs (6–10 mM VPA
lus  50 M PTX and 6–10 mM VPA plus 20–50 M PTX,
espectively). Moreover, the effect of the dual treatment
as signiﬁcant at 6 mM VPA plus 20–50 M PTX for G179
nd  10 mM VPA plus 50 M PTX for GliNS2. Lastly, GBM2
ell  line reached a 70% reduction in cell viability even at the
owest  doses of VPA and PTX (0.5 mM VPA and 0.1 M PTX).
his  effect was obtained by 6 mM VPA alone, whereas PTX
reatment, even at high doses, was unable to induce such
n  effect.
To determine the real effectiveness of the
ime-scheduled treatment (VPA exposure before PTX
reatment), cell viability was evaluated also with the
pposite arrangement. For this purpose, PTX 1 M was
dministered to GBM2 and G144 cell lines 24 h before VPA
reatment and the combined analysis revealed no additive
r  synergistic effect (data not shown, CI values reported in
able  S4), suggesting that the efﬁcacy of the dual treatmentrts 1 (2014) 188–199 195
is  associated with the administration timing and with the
speciﬁc  biological effect of each drug.
4. Discussion
Cultured GSC lines are a valuable model for testing
drug susceptibility. The genomic proﬁles of the 6 GSC
lines  used in this work were extensively characterized in
a  previous work by our research group [2]. Brieﬂy, the
GSCs  lines showed considerable karyotypic variability. The
modal  number of chromosomes spans from near-diploid to
near-pentaploid. Each cell line shows a complex karyotype
composed of both structural and numerical abnormalities.
The most common numerical aberration was gain of whole
chr  7, that was observed in the 70% of analyzed metaphases.
Other commonly observed numerical changes are loss of
chr  13 (43%), loss of sexual chromosomes (chr X 28% and chr
Y  39%) and loss of chr 10 (32%, 3 out of 6 lines). Chromosome
1 was  the most frequently involved in structural abnormal-
ities  (6/6 lines). Also chr 11 (3/6 lines), 18 and 12 (4/6 lines)
were  often rearranged. Moreover, chr 6 showed deletions
or  translocations involving the long arm in 3 out of 6 lines.
Array  CGH analysis showed some common genomic fea-
tures  in GSCs, such as loss of 9p21.3 locus (4/6 cell lines),
that  harbors CDKN2A and CDKN2B genes, pseudomono-
somy for whole chr 10 (3/6 lines), with the consequent
absence of PTEN gene, and complete or partial gain of chr
7  (4/6 lines), which contains EGFR gene.
Identifying a suitable approach for the eradication of the
stem  cell subpopulation of glioma is essential to achieve an
effective  treatment for GBM. In order to evaluate the thera-
peutic  efﬁcacy of a drug, it is appropriate to assess different
biological parameters, in order to have a comprehensive
view on the cellular action of the compound of interest.
In this study we analyzed the variations of two  cytoge-
netic parameters (polymorphic nuclei and mitotic index)
caused  by VPA or PTX administration and we performed a
cell  viability study by MTT  assay after single and combined
treatment with the two drugs, to detect a potential reduc-
tion  in proliferation and an effective cytotoxicity on cancer
cells.  This approach requires the formulation of a solid
method for the integration of data with various biologi-
cal  nature in order to interpret them together, speciﬁcally
obtaining a global evaluation of drug efﬁcacy.
Valproic acid (VPA) induces differentiation of several
types of cancer cells, both in vitro and in vivo [11,10] and
it  is able to permeate the blood brain barrier (BBB), with
minimal toxicity proﬁle, even after chronic treatment,
thus representing an attractive agent for cancer treatment
[44,56]. Several studies were conducted to characterize the
in  vitro neurotoxicological impact of VPA. In 1998, Fennrich
and  collegues demonstrated that 2.5 mM and 5 mM VPA
cause  toxic effects on organotipically cultured hippocampi
by  affecting speciﬁc populations of astrocytes [18]. More-
over,  Wang and collegues showed that 1 mM VPA exposure
for  7 days induces a weak increase of apoptotic cells in
neuron-enriched cultures, while 0.25–1 mM VPA selec-
tively causes neuronal apoptosis in a neuron–astrocyte
mixed cell culture, suggesting a synergism between the
two  cell types [60]. In our study, VPA inhibited cell growth
in  a dose- and time-dependent manner in all the GSC lines.
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d treatm
esults a
 5% of eFig. 5. Cell viability assays on GSC lines using VPA and PTX in combine
treated  cells relative to untreated cells. We show mortality percentages. R
in  triplicate. Standard error of the mean (SEM) was  constantly lower than
VPA is able to modify the expression of genes involved
in cell cycle, differentiation, DNA repair and apoptosis
[49,54]. Speciﬁcally, it stimulates p21 expression, inducing
G1/S  block of cell cycle [9], and simultaneously acti-
vates apoptotic program, through the down-regulation
of anti-apoptotic proteins, such as Bcl-2/Bcl-XL [67,32].
Indeed, we observed a mitotic index decrease after drug
treatment, conﬁrming a G1 block induced by VPA [46,42].
Moreover, VPA reduced the chromosome number scatter-
ing  and selectively depleted polyploid cells: only cells with
a  lower number of chromosome were able to continue in
the  cell cycle, whereas the others were negatively selected
(data  not shown). This behavior can be translated into
a  change in nuclear morphology compared to untreatedent. Cell viability was measured as percentage of cell survival in drug-
re reported as means from two different experiments performed at least
ach mean value. *CI < 1, synergistic effect; §CI  = 1, additive effect.
cells, as also described by [30]. Probably, VPA induced a
decrease  in cell viability by inhibition of cell proliferation
and induction of differentiation, rather than by apoptosis
[23]. Generally, cells arrested in G1 phase evolve toward
differentiation and this process is mutually exclusive
with apoptosis [4]. Anyway, the factors determining
cell fate (cycle arrest, differentiation or apoptosis) are
still  unknown. Afterwards, we demonstrated that VPA
treatment strongly modiﬁes cellular morphology and
expression of stemness (CD133 and Nestin) and differenti-
ation (GFAP, ˇIII-tubulin and MBP) markers in all the GSC
lines.  Although with a remarkable interlinear variability,
VPA triggered a differentiation-like process, which may
reﬂect  the differentiative potential or the differentiation
gy Repo
b
s
u
r
t
d
I
o
c
t
t
a
a
i
f
h
m
m
e
i
o
o
4
s
p
d
c
c
m
m
p
l
t
a
i
i
p
i
d
l
o
e
i
b
x
t
w
t
s
u
[
t
t
c
t
G
M
i
sG. Riva et al. / Toxicolo
lock of each cell line. Regarding the VPA responsivity
core, we suggested the good efﬁcacy of this drug, allowing
s  to classify GSC lines from the most sensitive to the least
esponsive: G166, G179 and G144, GBM2, GBM7, GliNS2.
Paclitaxel (PTX) is a mitotic inhibitor, which binds to
he  ˇ-subunit of tubulin in microtubules, stabilizing their
ynamics, leading to mitotic arrest and apoptosis [27].
n  our study PTX had a weak effect on GSC lines and
nly GBM2 cell line showed a considerable decrease in
ell  viability after 72 h exposure. PTX treatment is able
o  induce a G2/M block, which leads to the accumula-
ion of mitotic ﬁgures, increasing the mitotic index, as
n  expected consequence [55]. The induction of mitotic
rrest is the primary mechanism of action of drugs affect-
ng  microtubule dynamics [22]. Cells remained in mitosis
or  up to 24 h and then attempted to complete mitosis,
owever cytokynesis remained inhibited and cells became
ultinucleated or polyploid, as also described by Lieb-
ann and collegues in 1994. Escaping from mitosis and
ntering interphase is termed “mitotic slippage” [16] and
t  induces a multinucleated grape-like nuclear morphol-
gy of slipped cells, identiﬁed as an increased percentages
f  polymorphic nuclei, as already highlighted by [48]. After
8  h treatment, the percentage of mitotic cells decreased,
howing that the initially blocked cells attempt to com-
lete  mitosis. Cells escaping mitotic block bypass cellular
ivision and this process results in endoreduplication and,
onsequently, polyploidization [33]. Subsequently, these
ells  undergo a non-apoptotic form of cell death, known as
itotic  catastrophe [17]. Cells insensitive to PTX treatment
ay  have mutations in genes involved in the mitotic check-
oint,  which accelerate mitotic process and reduce mitosis
ength:  in 2009, Yang and collegues demonstrated that
hese  cells did not show accumulation of mitotic ﬁgures
fter  PTX treatment for 24 h [64]. The decrease of mitotic
ndex in barely sensitive cells may  be linked to a general
nduction of apoptosis by PTX, that may  occur via signaling
athways independent from mitotic arrest [8]. The variabil-
ty  in response to mitotic stress in GSC lines reﬂects their
ifferential sensitivity to drug treatment and cytomorpho-
ogical parameters may  represent an important indicator
f  pathological response to drug administration [7]. PTX is
xtensively  used in several types of solid cancer [50] and
t  has been recently shown to have a therapeutic effect
oth in vitro on glioma cells [66] and in vivo on GBM
enografts in mice [28,29]. The weak permeability of PTX to
he  BBB may  be a limiting aspect in clinical practice, any-
ay  BBB integrity is often compromised in GBM patient,
he  blood capillaries are leaky [12] and moreover, several
trategies to improve PTX delivery in the brain, such as the
se  of engineered nanoparticles, are under investigations
63].
With regard to PTX responsivity score, we noted
he limited effectiveness of this drug on the GSC lines
ested (except for G179 line), bearing witness to the high
hemoresistance of GBM. This behavior could be related to
he  partial or complete gain of chromosome 7 in all the
SC  lines of the study [2]. Indeed, at 7p22.3 is mapped
AD1L1 gene, a component of mitotic checkpoint, which
s  able to confer chemoresistance to microtubule poisons,
uch  as PTX, when up-regulated [52].rts 1 (2014) 188–199 197
To overcome the limitations linked to a single agent
therapy, we decided to combine VPA and PTX in order
to  verify the effect of this dual treatment on GSC via-
bility. We  utilized VPA as a sensitizer agent in order to
improve the PTX effectiveness through the induction of dif-
ferentiation triggered by HDAC inhibitors [14]. Speciﬁcally,
differentiation-inducing therapies are the most promis-
ing  treatments, in order to affect the self-renewal ability
of  the cancer stem cell subpopulation. The ability of VPA
to  induce differentiation is the rationale for its use in
a  combined treatment: the induction of GSC differentia-
tion and the reduction of cell proliferation can be coupled
with  a drug able to promote cell death, such as PTX [51].
After  VPA induced-differentiation, PTX might be able to
inﬂuence cell viability of cells downstream in the hier-
archical composition of GBM. Globally, cell death was
increased after dual treatment in all the GSC lines, thus
VPA  enhanced the anticancer action in combination with
PTX.  Five cell lines (GBM2, GBM7, G144, G179, GliNS2)
showed an increased synergism at lower concentrations of
both  drugs: when using lower doses, toxicity can be mini-
mized  and therapeutic efﬁcacy maintained. This approach
is  strictly dependent on time-scheduled administration:
reverse treatment, indeed, did not display any synergism.
The clinical use of PTX is hampered by its severe side
effects [6], but they are chieﬂy dependent upon high dose
regimens and on Cremophor EL, which is used as vehi-
cle  [43]. In particular, PTX neurotoxicity is caused by the
disruption of microtubule structure and axonal degen-
eration, that lead to the impairment of the axoplasmic
transport: LaPointe and collegues reported that a 10 M
PTX  dose is able to induce such effect [34]. Ustinova and
collaborators demonstrated that 0.1 nM and 0.5 nM PTX
do  not inﬂuence the neuronal growth in cultures, but
higher concentrations of PTX (1–10–100 nM)  have signiﬁ-
cant  toxic effects on murine dorsal root ganglion neurons
[59].  VPA administration may  consent the reduction of
PTX  concentration, maintaining the same killing effect and
allowing  an effective treatment [5]. The effectiveness of
VPA  combined with PTX administration was due to the
ability  of VPA to enhance the sensitivity to chemother-
apeutic agents [41]. Alternatively, since VPA induces ˛
tubulin  acetylation [5], which could suppresses micro-
tubule dynamics, VPA may  positively affect PTX binding
to  microtubules.
Collectively, the combination of VPA and PTX could be
a  real potential therapeutic strategy to speciﬁcally erad-
icate  GSCs and might provide insights for the design of
new  clinical treatments of GBM. Lastly, our multiple drug
responsivity assay could represent a useful tool to assess
the  efﬁcacy of different antineoplastic drugs because it
relies  on the evaluation of multiple cell parameters, whose
results  are in this way  integrated; in the future, this method
could  help to select the right treatment and to perform
optimal drug combinations.Funding
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